Company Overview
Snapshot
Founded in January 2025, CLISEQ operates with 1–10 employees and has completed two funding rounds. The company is advancing minimally invasive diagnostic approaches for hematologic disorders, leveraging a patented technology from the Weizmann Institute of Science.
Business overview
CLISEQ is a translational diagnostics company specializing in hematology diagnostics. Spun out of the Weizmann Institute of Science, the company develops minimally invasive diagnostic approaches for hematologic disorders using a patented technology that enables peripheral blood single-cell RNA sequencing (scRNA-seq). This technology aims to detect conditions like myelodysplastic syndromes (MDS) as an alternative to bone-marrow aspiration. CLISEQ serves the healthcare and life sciences sectors, focusing on patients and clinical diagnostics.
Strategic signal
In September 2025, CLISEQ announced a collaboration with 10x Genomics and the Weizmann Institute to investigate single-cell applications in hematology clinical diagnostics. This partnership is significant as it validates CLISEQ's technology through an international multi-site clinical trial (PERIBLOOD) involving over 1,500 participants, signaling strong progress towards clinical utility and future diagnostic workflows in hematology.
Log in to access full profile ›Company Intelligence Q&A
- What is CLISEQ's core focus?
- CLISEQ is a translational diagnostics company focused on advancing minimally invasive diagnostic approaches for hematologic disorders, utilizing peripheral blood single-cell RNA sequencing (scRNA-seq).
- When was CLISEQ founded?
- CLISEQ was founded in January 2025 as a spin-out from the Weizmann Institute of Science.
- What is the significance of CLISEQ's technology?
- CLISEQ holds exclusive rights to a patented technology developed at the Weizmann Institute that enables the use of peripheral blood single-cell RNA sequencing (scRNA-seq) to detect conditions such as myelodysplastic syndromes (MDS), offering a less invasive alternative to bone-marrow aspiration.
- Has CLISEQ engaged in any notable collaborations?
- In September 2025, CLISEQ announced a collaboration with 10x Genomics and the Weizmann Institute to investigate single-cell applications in hematology clinical diagnostics. This partnership supports an international multi-site clinical trial (PERIBLOOD) to validate the technology's clinical utility.
- What is the status of CLISEQ's product development?
- CLISEQ's product is currently in the clinical trial stage, with the PERIBLOOD study enrolling over 1,500 participants across several continents to validate its diagnostic technology.